IE
EPRX

Israel Englander’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Israel Englander’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.92M Buy
+441,586
New +$3.04M ﹤0.01% 3506
2025
Q1 		– Sell
-10,000
Closed -$31.3K – 6504
2024
Q4 		$31.3K Buy
+10,000
New +$29.6K ﹤0.01% 5661

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Israel Englander's EPRX Position: Q2 2026 in Review

Israel Englander opened a new position in Eupraxia Pharmaceuticals (EPRX) in Q2 2026: 441,586 shares worth $2.92M. The stake represents ﹤0.01% of the portfolio and ranks #3506 among its holdings. This is a return to the name: Israel Englander previously reported a position in EPRX as recently as Q4 2024.

Israel Englander first reported a position in EPRX in Q4 2024 and has held it in 2 quarters since. 68 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

  • Israel Englander held 441,586 shares of Eupraxia Pharmaceuticals worth $2.92M as of Q2 2026.
  • Eupraxia Pharmaceuticals was a new Israel Englander position in Q2 2026.
  • Eupraxia Pharmaceuticals made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3506 holding.
  • Israel Englander first reported a position in Eupraxia Pharmaceuticals in Q4 2024 and has held it in 2 quarters since.
  • 68 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.